Lipoprotein-associated phospholipase A2 is increased in patients with impaired bone density

• Main Authors: Kotaška Karel, Kolářová Jitka, Jedličková Blanka, Čepová Jana, Kotaška Jan, Průša Richard
• Format: Article
• Language: English
• Published: Society of Medical Biochemists of Serbia, Belgrade 2014-01-01
• Series: Journal of Medical Biochemistry
• Subjects: lipoprotein-associated phospholipase a2; osteocalcin; bone metabolism
• Online Access: https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2014/1452-82581404317K.pdf
• ISSN: 1452-8258; 1452-8266

Background: Increased levels of lipoprotein-associated phospholipase A2 are associated with atherosclerosis, and may contribute to cardiac disease. The aim of this study was to analyze serum levels of lipoprotein phospholipase A2 (Lp-PLA2) in patients with impaired bone resorption and correlate the findings with markers of bone metabolism (osteocalcin) and other biochemical markers (cholesterol, low density lipoprotein, triacylglycerols). Methods: Serum Lp-PLA2 was measured by a turbidimetric method in a group of currently treated 85 patients with impaired bone resorption and in a control group of 46 healthy individuals. Serum triacylglycerols was measured by the electrochemiluminescence immunoassay. Cholesterol, low density lipoprotein and triacylglycerols were measured by commercially available enzymatic assays. Bone density was investigated by dual energy X-ray densitometry performed on the lower spine and hips. Results: Concentrations of LP-PLA2 were significantly elevated in the patients with bone resorption compared to the control group of healthy individuals (225 ng/mL vs. 192 ng/mL, p< 0.001) with the highest difference in patients with a T score below -2.5 SD (227 vs. 192 ng/mL). Serum levels of Lp-PLA2 also negatively correlated with decreased levels of serum osteocalcin in patients, and a significant difference in Lp-PLA2 (p= 0.02) levels was observed between the control group and group with low levels of osteocalcin. Elevated Lp-PLA2 levels were significantly associated with the therapeutic procedures used, but not with age, gender and concentration of lipids. Conclusions: Lipoprotein-associated phospholipase A2 seems to play an important role also in bone metabolism.